Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Shares Gap Down – What’s Next?

Bayer Aktiengesellschaft (OTCMKTS:BAYRY)’s share price gapped down prior to trading on Friday . The stock had previously closed at $10.94, but opened at $10.50. Bayer Aktiengesellschaft shares last traded at $10.48, with a volume of 189,266 shares.

Wall Street Analyst Weigh In

BAYRY has been the topic of a number of recent research reports. Zacks Research upgraded shares of Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Friday, May 8th. UBS Group upgraded shares of Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, May 19th. Three equities research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy”.

Bayer Aktiengesellschaft Stock Performance

The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $41.70 billion, a PE ratio of -16.58, a P/E/G ratio of 3.51 and a beta of 0.62. The firm’s 50-day moving average price is $11.25 and its two-hundred day moving average price is $11.21.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.79 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.15. The firm had revenue of $15.73 billion for the quarter, compared to analysts’ expectations of $15.77 billion. Bayer Aktiengesellschaft had a negative net margin of 4.75% and a positive return on equity of 17.74%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. As a group, research analysts predict that Bayer Aktiengesellschaft will post 1.25 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.